Director at Bristol Myers Squibb (NYSE: BMY) awarded 3,996.367 deferred share units

Rhea-AI Filing Summary

Bristol Myers Squibb director Peter J. Arduini reported an equity compensation grant. On February 1, 2026, he was awarded 3,996.367 Deferred Share Units at $55.05 per unit, increasing his total holdings to 70,858.084 Deferred Share Units.

Each Deferred Share Unit will convert into one share of common stock when the award is settled. The units become settleable when Arduini ceases to be a director or on a future date he previously selected. The reported balance includes deferred compensation and dividends reinvested under the company’s deferred compensation plan for non-employee directors.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Arduini Peter J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	3,996.367	$55.05	$220K

Holdings After Transaction: Deferred Share Units — 70,858.084 shares (Direct)

Footnotes (1)

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arduini Peter J

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	02/01/2026		A		3,996.367		(1)	(1)	Common Stock, $0.10 par value	3,996.367	$55.05	70,858.084(2)	D

Explanation of Responses:

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Peter J. Arduini	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bristol Myers Squibb (BMY) disclose in this Form 4 filing?

Bristol Myers Squibb (BMY) disclosed that director Peter J. Arduini received 3,996.367 Deferred Share Units as equity compensation. These units are linked to the company’s common stock and increase his total deferred share unit holdings to 70,858.084 units.

How many Deferred Share Units did BMY director Peter J. Arduini receive?

Peter J. Arduini received 3,996.367 Deferred Share Units from Bristol Myers Squibb. The units were credited at a reference price of $55.05 per unit, representing additional deferred director compensation tied to the company’s common stock performance over time.

At what price were the Bristol Myers Squibb Deferred Share Units credited?

The Deferred Share Units were credited at a reference price of $55.05 per unit. This price is used to determine how many units are issued under the deferred compensation arrangement, rather than representing an open-market stock purchase by the director.

When will Peter J. Arduini’s Deferred Share Units in BMY convert into common stock?

Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified under the company’s deferred compensation program.

How many Deferred Share Units does the BMY director hold after this transaction?

After this transaction, Peter J. Arduini beneficially owns 70,858.084 Deferred Share Units. This figure includes prior deferred compensation amounts and dividends reinvested under Bristol Myers Squibb’s 1987 Deferred Compensation Plan for Non-Employee Directors.

Does this BMY Form 4 filing involve open-market buying or selling of shares?

The filing reflects an award of Deferred Share Units, not open-market buying or selling. These units are part of a deferred compensation arrangement for a non-employee director and will convert into common stock at settlement rather than through immediate market transactions.